NASDAQ:DSGN Design Therapeutics Q3 2025 Earnings Results & Report $10.65 -0.15 (-1.39%) Closing price 11/10/2026 04:00 PM EasternExtended Trading$10.66 +0.01 (+0.14%) As of 11/10/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Design Therapeutics beat analyst earnings expectations in its Q3 2025 results, released November 5, 2025. The company reported EPS of -$0.30 versus the -$0.34 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 5, 2025TimeBefore Market OpensConference Call7:00 AM ET Design Therapeutics EPS ResultsActual EPS-$0.30Consensus EPS -$0.34Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersDesign Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Design Therapeutics Q3 2025 Earnings FAQ Did Design Therapeutics beat earnings estimates for Q3 2025? Design Therapeutics (NASDAQ:DSGN) reported earnings of -$0.30 per share for Q3 2025, beating the consensus estimate of -$0.34. The report was announced on Wednesday, November 5, 2025. Design Therapeutics Earnings HeadlinesDesign Therapeutics (NASDAQ:DSGN) Rating Lowered to Sell at Wall Street ZenNovember 7, 2026 | americanbankingnews.comDesign Therapeutics (NASDAQ:DSGN) Price Target Cut to $19.00 by Analysts at Royal Bank Of CanadaNovember 6, 2026 | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)RBC Cuts Price Target on Design Therapeutics to $19 From $20, Keeps Outperform, Speculative RiskNovember 5, 2026 | marketscreener.comMDesign Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMDesign Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business UpdatesNovember 4, 2026 | finance.yahoo.comSee More Design Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Design Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Design Therapeutics and other key companies, straight to your email. Email Address About Design TherapeuticsDesign Therapeutics (NASDAQ:DSGN) is a clinical-stage biotechnology company developing medicines for inherited diseases. Its research focuses on conditions associated with genetic repeat expansions, in which repeated DNA sequences can disrupt the normal activity of a gene. The company’s GeneTAC platform is designed to create small molecules that interact with these expanded genetic sequences and help restore gene expression. Design Therapeutics aims to use this approach to address the underlying causes of disease rather than only manage symptoms. Its pipeline includes DT-216, an investigational candidate being developed for Friedreich ataxia, a rare inherited disorder associated with reduced production of frataxin. Design Therapeutics is based in California and has focused its drug-development work on genetic diseases with significant unmet medical needs.View Design Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
